June 1, 2020 / 8:21 PM / a month ago

BRIEF-Relief Therapeutics, Neurorx Announce Enrollment Of First Patients With Rlf-100 In Phase 2B/3 Clinical Trial In Patients With Covid-19 Associated Acute Respiratory Distress

June 1 (Reuters) - RELIEF THERAPEUTICS Holding SA:

* RELIEF THERAPEUTICS AND NEURORX ANNOUNCE ENROLLMENT OF FIRST PATIENTS WITH RLF-100 IN PHASE 2B/3 CLINICAL TRIAL IN PATIENTS WITH COVID-19 ASSOCIATED ACUTE RESPIRATORY DISTRESS

* RELIEF THERAPEUTICS - MULTICENTER RANDOMIZED PLACEBO-CONTROLLED TRIAL AIMS TO ENROLL 120 PATIENTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below